Chroniques génomiques - Séquençage d’ADN, la fin d’un quasi-monopole ?

Jordan, Bertrand

doi:10.1051/medsci/2023061

dc.contributor.author	Jordan, Bertrand	-
dc.date.accessioned	2023-12-29T11:48:23Z
dc.date.available	2023-12-29T11:48:23Z
dc.date.issued	2023
dc.identifier.citation	Jordan, Bertrand ; Séquençage d’ADN, la fin d’un quasi-monopole ? : Chroniques génomiques, Med Sci (Paris), Vol. 39, N° 5 ; p. 469-473 ; DOI : 10.1051/medsci/2023061
dc.identifier.issn	1958-5381
dc.identifier.uri	http://hdl.handle.net/10608/14537
dc.description.abstract	DNA sequencing costs have steadily decreased during the last decade, but the dominant technology (short-read sequencing, Illumina) has seen comparatively little competition after an initial flurry. This phase is now over, with serious competition involving both established and new companies as well as the growing importance of long-read sequencing. The hundred-dollar genome is in sight, and this will have a major impact on many fields of biology.	en
dc.language.iso	fr
dc.publisher	EDP Sciences
dc.relation.ispartof	Forum
dc.rights	Article en libre accès - License CC BY 4.0	fr
dc.rights	Médecine/Sciences - Inserm - SRMS	fr
dc.rights.uri	http://creativecommons.org/licenses/by/4.0
dc.source	M/S. Médecine sciences [ISSN papier : 0767-0974 ; ISSN numérique : 1958-5381], Vol. 39, N° 5; p. 469-473
dc.subject.mesh	Humains	fr
dc.subject.mesh	Analyse de séquence d'ADN	fr
dc.subject.mesh	Génome	fr
dc.subject.mesh	Séquence nucléotidique	fr
dc.subject.mesh	Séquençage nucléotidique à haut débit	fr
dc.title	Chroniques génomiques - Séquençage d’ADN, la fin d’un quasi-monopole ?	fr
dc.title.alternative	End of a near-monopoly on DNA sequencing	en
dc.type	Article
dc.contributor.affiliation	Biologiste, généticien et immunologiste, Président d’Aprogène (Association pour la promotion de la Génomique) , 13007 Marseille , France
dc.identifier.doi	10.1051/medsci/2023061
dc.identifier.pmid	37219353